以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗器械板块主力资金净流出6.22亿元，游资资金净流入8454.45万元，散户资 金净流入5.38亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300049 | 福瑞股份 | 1.46 Z | 11.88% | -1.05 Z | -8.52% | -4138.97万 | -3.36% | | 300003 | 乐普医疗 | 1.21 Z | 7.97% | -5108.00万 | -3.37% | -6962.47万 | -4.59% | | 600645 | 中源协和 | 9348.49万 | 9.75% | -3949.64万 | -4.12% | -5398.85万 | -5.63% | | 688271 | 联影医疗 | ...

国金证券对浩瀚深度控股股东、实际控制人一致行动协议到期不再续签暨权益变动事项核查。2013年12 月张跃和雷振明签署《一致行动人协议》及《补充协议》，2025年8月18日到期后不再续签，一致行动 关系19日起解除。 ...

Group 1 - The A-share market experienced a strong upward trend on August 18, with the Shanghai Composite Index reaching a nearly 10-year high [1] - The STAR Market Composite Index ETF by Huatai-PB rose by 1.94%, indicating positive market sentiment [1] - The STAR Market Composite Index itself surged by 2.08%, with notable gains from constituent stocks such as Nanxin Pharmaceutical and Shunlian Bio, both increasing by over 20% [1] Group 2 - As of August 18, 2025, the top ten constituent stocks of the STAR Market ETF include companies like Saiwei Technology and Haiguang Information, with varying performance in terms of price changes and trading volumes [2] - The semiconductor industry in China saw a total investment of 455 billion yuan in the first half of 2025, reflecting a 9.8% year-on-year decline, while semiconductor equipment investment grew by 53.4%, highlighting a strategic focus on supply chain autonomy [3] - Major global tech companies are significantly increasing their capital expenditures for AI infrastructure, with Microsoft planning to spend $88.2 billion in the 2025 fiscal year, followed by Google and Meta with substantial increases as well [3][4]

Core Insights - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index has shown a positive trend, with notable increases in constituent stocks such as Yirui Technology (up 14.00%) and Microelectronic Physiology (up 11.01%) [1][3] - The Jiashi Sci-Tech Medicine ETF has experienced significant trading activity, with a turnover rate of 28.3% and a total transaction volume of 71.52 million yuan, indicating a vibrant market [3] Market Performance - As of August 15, 2025, the Jiashi Sci-Tech Medicine ETF has achieved a net value increase of 56.25% over the past year, with a maximum single-month return of 23.29% since its inception [3] - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [3][5] Policy and Industry Trends - Recent national regulations aim to enhance drug accessibility and reduce patient burdens, promoting the circulation of pharmaceuticals and releasing more policy dividends for the innovative drug market [5] - The pharmaceutical and chemical manufacturing sectors are undergoing significant policy reforms and global transformations, focusing on drug procurement optimization and supply chain security [6]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [5]. Core Insights - The initial review of the commercial insurance innovative drug directory has been approved, indicating a continuous expansion of payment space [2][21]. - The report highlights the importance of focusing on companies with strong R&D capabilities and existing commercialized innovative drug products, such as BeiGene, Hengrui Medicine, Innovent Biologics, and Kangfang Bio [2][25]. Summary by Sections Market Review - Last week, the A-share pharmaceutical and biotechnology index rose by 3.08%, outperforming the CSI 300 index by 0.77 percentage points, but underperforming the ChiNext index by 2.76 percentage points, ranking 10th among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Medical Health Index increased by 7.12%, outperforming the Hang Seng Index by 5.51 percentage points [1][15]. Company R&D Progress - Recent IND applications include Hengrui Medicine's HRS-4729 injection and HRS-7172 tablets, as well as clinical applications for Kangnuo's CM536 injection and Sanofi's SSS50 injection [28]. Key Company Profit Forecasts and Valuation - Hengrui Medicine: EPS forecast for 2024 is 0.99 CNY, with a PE ratio of 64, rated as "Accumulate" [4]. - Yuyue Medical: EPS forecast for 2024 is 1.80 CNY, with a PE ratio of 20, rated as "Buy" [4]. - Mindray Medical: EPS forecast for 2024 is 9.62 CNY, with a PE ratio of 24, rated as "Buy" [4]. - United Imaging Healthcare: EPS forecast for 2024 is 1.53 CNY, with a PE ratio of 84, rated as "Buy" [4]. Payment Perspective Strategy - The report emphasizes the need to select investment opportunities structurally, focusing on the core contradiction between payment willingness and ability [3][25]. - It identifies three key payment channels: hospital payments, out-of-pocket payments, and overseas payments, recommending companies like Hengrui Medicine, Mindray Medical, United Imaging Healthcare, and Yuyue Medical [3][25]. Innovative Drug Directory Insights - A total of 121 drugs passed the initial review for the commercial insurance innovative drug directory, with 79 drugs appearing in both the basic medical insurance and commercial insurance directories, providing a "double insurance" effect [2][22]. - The report notes that targeted therapies, particularly PD-(L)1 monoclonal antibodies, dominate the applications for the commercial insurance directory [2][23].

Core Viewpoint - The article discusses the performance of the Science and Technology Innovation ETF (科创ETF, 588050), highlighting its recent gains and the performance of its major holdings [1]. Group 1: ETF Performance - The Science and Technology Innovation ETF (588050) opened with a gain of 1.06%, priced at 1.146 yuan [1]. - Since its establishment on September 28, 2020, the ETF has recorded a return of -21.05%, while its return over the past month has been 10.56% [1]. Group 2: Major Holdings - Key stocks within the ETF include: - SMIC (中芯国际) up by 1.81% - Haiguang Information (海光信息) up by 0.74% - Cambricon (寒武纪) up by 2.88% - Lattice Semiconductor (澜起科技) up by 0.02% - Zhongwei Company (中微公司) up by 0.77% - Kingsoft Office (金山办公) up by 0.48% - United Imaging (联影医疗) up by 0.38% - Transsion Holdings (传音控股) up by 0.07% - Ninebot (九号公司) up by 0.10% - Chipone (芯原股份) up by 2.69% [1].

本周外盘看点 上周国际市场风云变幻，美国通胀指标喜忧参半，美国总统特朗普与俄罗斯总统普京举行会晤。美股全 线走高，道指累计上涨1.75%。标普500上涨0.93%，纳斯达克综合指数上涨0.79%。欧洲三大股指表现 不俗，英国富时100指数周涨0.47%，德国DAX 30指数周涨0.81%，法国CAC 40指数周涨2.33%。 本周看点颇多，美联储主席鲍威尔在杰克逊霍尔研讨会上的评论，以及美联储最近一次会议纪要广受市 场关注，因为投资者越来越相信下个月将恢复降息；在欧洲，英国的通货膨胀数据、8月采购经理人调 查PMI将公布；在亚洲，随着加息押注的步伐加快，日本的通胀数据将受到关注。全球央行中，本周瑞 典、新西兰和印度尼西亚等将召开议息会议。 美联储9月降息信号 按照日程安排，美联储主席鲍威尔将于下周五在怀俄明州杰克逊霍尔举行的年度央行会议上就经济前景 和美联储对其政策框架的审查发表演讲。会议从周四持续到周六，今年的主题是"转型中的劳动力市 场：人口、生产力和宏观经济政策"。 最近疲软的美国就业数据，以及特朗普关税对价格的影响尚未完全显现，投资者预计美联储将在9月降 息。机构LBBW在一份报告中表示，鲍威尔在杰克 ...

首次覆盖方面，8月11日至8月15日券商共给出了95次首次覆盖，其中天山股份获得西部证券给予"买 入"评级，北汽蓝谷获得天风证券给予"买入"评级，燕京啤酒获得华源证券给予"增持"评级，海容冷链 获得国泰海通证券给予"增持"评级，新洋丰获得华金证券给予"买入"评级。 免责声明：文中涉及的观点、数据、个股等要素仅供参考，不构成投资建议，操作风险自担，投资有风 险，入市需谨慎。 评级调低方面，8月11日至8月15日，券商调低上市公司评级达到8家次，最新数据包括了华泰证券对德 邦股份的评级从"增持"调低至"持有"，华创证券对甘源食品的评级从"强推"调低至"推荐"，东吴证券对 健盛集团的评级从"买入"调低至"增持"。 南财投研通数据显示，8月11日至8月15日，券商给予上市公司目标价共217次，按最新收盘价计算，目 标价涨幅排名居前的公司有贵州茅台、云天化、晶晨股份，目标价涨幅分别为82.83%、59.38%、 54.93%，分别属于白酒、农化制品、半导体行业。 从券商推荐家数来看，8月11日至8月15日有294家上市公司得到券商推荐，其中贵州茅台获得34家推 荐，燕京啤酒获得21家推荐，万华化学获得21家推荐。 评级 ...

2025.08. 18 【今日推荐】 美俄乌三方会晤有望举行？美乌态度积极 普京提和平没提会晤 俄美元首阿拉斯加会晤后，美国总统特朗普16日表示，将与乌克兰总统泽连斯基于美东时间18日下 午在白宫椭圆形办公室会面。如果一切顺利，接下来将安排美国、俄罗斯、乌克兰三方领导人会晤。 就此，泽连斯基表示，乌支持举行乌美俄三方会晤的提议。普京16日在克里姆林宫举行的会议中并 未提及三方会议相关内容。18日的华盛顿之行将是自今年2月在白宫与特朗普会面后，泽连斯基首次 前往美国。 普京向多国领导人通报情况 据央视新闻，当地时间17日，克里姆林宫新闻局发布消息称，俄罗斯总统普京当天先后与白俄罗斯 总统卢卡申科、哈萨克斯坦总统托卡耶夫、乌兹别克斯坦总统米尔济约耶夫通电话，通报了他与美国 总统特朗普在阿拉斯加会晤的情况。 特朗普：在俄罗斯问题上取得重大进展 当地时间8月17日，美国总统特朗普在其社交媒体"真实社交"上发文称，"在俄罗斯问题上取得重大进 展"，并呼吁外界"拭目以待"。 胡塞高超音速导弹再袭以色列机场 据CCTV国际时讯报道，当地时间8月17日晚，也门胡塞武装发言人叶海亚·萨雷亚发表视频声明称， 胡塞武装当天使用一枚 ...

第一财经每日早间精选热点新闻，点击「听新闻」，一键收听。 【今日推荐】 特朗普：在俄罗斯问题上取得重大进展 【观国内】 国新办发表《2024年美国侵犯人权报告》 国务院新闻办公室17日发表《2024年美国侵犯人权报告》，揭示在权力与资本合谋之下，美式人权被异化为政治"秀场"上的道具和权力"赌场"中的筹码，背 离了人权的核心价值和本质要求。报告分为"序言""美式民主：金权游戏的狂欢""民生福祉：底层民众的挣扎""种族主义：少数族裔的枷锁""脆弱群体：妇女 儿童的无助""致命旅途：无证移民的悲歌""美式霸权：他国人权的梦魇""结语"等部分。 我国中东部大范围高温闷热天气持续发力 华南等地仍有强降雨 8月17日至18日，受南海热带低压和季风气流的共同影响，西南、华南等地的强降雨将持续发力，同时华北、东北地区还会迎来降雨和强对流天气的"组合 拳"。未来10天，随着副热带高压继续加强西伸北抬，高温闷热天气会向北扩展，高温核心区域的四川盆地、浙江等地最高气温可达40℃以上。 我国首个搭载气象雷达的海上升压站完成安装 8月16日，我国首个搭载气象雷达的海上升压站，在三峡江苏大丰800兆瓦海上风电项目现场完成安装，该设施将实 ...